WHAT REGION ARE YOU IN?
X

Disease apps for clinics

ACTIONABLE INSIGHTS FOR RETINAL DISEASES
The challenge

Despite advances in retinal imaging technology, patient disease activity can be missed in vision-threatening conditions. This oversight in everyday practice has the potential for undertreatment in patients. In addition, treatment delays further impact vision, worsening outcomes. Delays are in part due to a lack of awareness and urgency from the patient.

The Solution: RetinAI's Disease Apps for Disease Management

RetinAI’s Disease Evaluation Apps are accessed via Heidelberg AppWay. AppWay is a secure data transfer portal integrated in Heidelberg’s HEYEX 2.6. The Disease Apps provide expert-level analysis of a patient’s OCT volumes. Results are generated during the patient’s visit to complement evaluation and management of retinal diseases. The results can be used to better understand disease and status of biomarkers, and can provide valuable education and visualization of disease and biomarkers, empowering patients to be engaged in their disease management.

RetinAI’s Disease Evaluation Apps powered by Certified* AI Models:

RetinAI’s Disease Evaluation Apps are made up of a set of CE-Marked AI models that are approved for clinical use.

These models were developed from real world evidence across multiple retinal diseases comparing the models’ performance to that of expert graders, resulting in similar performance achieved.

These models were designed to provide valuable insights for patient management.
Register
*RetinAI’s fluid, layer and macula biomarkers models are CE-marked in the European Union, and approved for clinical use. Use of these models outside the EU, and other models deemed as research use only (RUO), requires users to obtain approvals to use them for human factors research or clinical evaluation.''

FLUID SEGMENTATION MODEL

Identifies and quantifies the volume of pathological fluid such as intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelium detachment (PED).

LAYER SEGMENTATION MODEL

MEASURES TOTAL RETINAL AND LAYER THICKNESS FOR THE FOLLOWING LAYERS:

Retinal Nerve Fiber Layer (RNFL; Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL); Inner Nuclear Layer (INL) + Outer Plexiform Layer (OPL); Outer Nuclear Layer (ONL); Photoreceptor (PR) + Retinal Pigment Epithelium (RPE; and Choriocapillaris (CC) + Choroidal Stroma (CS).

MACULA BIOMARKERS MODEL

PROVIDES PROBABILITY OF PRESENCE/ABSENCE OF RETINAL BIOMARKERS AT A B-SCAN LEVEL IN OCT VOLUMES. THE BIOMARKERS IDENTIFIED ARE:

Fluids (SRF, IRF and Fibrous PED), Hyper reflective Foci (HF), Drusen, Reticular Pseudodrusen (RPD), Epiretinal Membrane (EPM), Geographic Atrophy (GA) and Outer Retinal Atrophy (ORA).

RetinAI’s Disease Evaluation Apps on Heidelberg AppWay

A retinal disease is generally heterogenous in its presentation across eyes, across patients and across treatments.
As a result, to comprehensively understand a patient’s disease, it’s important to monitor relevant endpoints and biomarkers to obtain a full picture of the patient’s imaging data. RetinAI’s Disease Evaluation Apps provide the ability to quickly quantify relevant biomarkers to monitor changes across commonly managed diseases in Retina.


COMING SOON IN AUTUMN 2022 AFTER HEYEX 2.6 IS RELEASED
Dry AMD App
nAMD, DR/DME, CME App
Geographic Atrophy App
Fluid Segmentation
Comming soon as Research Use Only (RUO)
Layer Segmentation
Macular Biomarkers

If you are interested in knowing when the Apps become available
please register below for updates.

You will be able to purchase subscriptions to our Apps when HEYEX 2.6 is released.
If you have a standalone version of AppWay already, please contact us
The disease evaluation apps via AppWay, are meant to provide insights during a patient's visit.
If you are interested in batch data analysis using AI, read more about our RetinAI Discovery CORE®
RetinAI’s Apps on AppWay
Video Heading
EXPERT-LEVEL APPS
VIA Heidelberg appway

Resources with legal documents

Be prepared for checkout. Have remaining documents checked.

Want to use RetinAI's Apps on other devices?

Contact us at info@retinai.com to learn about other ways for accessing RetinAI’s Disease Evaluation Apps for your clinic.

*Disclaimer

RetinAI Discovery® and the AI models are CE-Marked medical devices according to the Medical Devices Directive 93/42/EEC.
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.

Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.